Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center Journal Article

   

Authors:	Schlappe, B. A.; Mueller, J. J.; Zivanovic, O.; Gardner, G. J.; Roche, K. L.; Sonoda, Y.; Chi, D. S.; O'Cearbhaill, R. E.
Article Title:	Cited rationale for variance in the use of primary intraperitoneal chemotherapy following optimal cytoreduction for stage III ovarian carcinoma at a high intraperitoneal chemotherapy utilization center
Abstract:	Objective Studies have demonstrated improved ovarian cancer survival with the administration of a combination of intravenous (IV) and intraperitoneal (IP) chemotherapy following optimal cytoreduction. Despite this, IV/IP chemotherapy is not uniformly used. In this retrospective cohort study, we assessed the documented reasons for giving IV-only chemotherapy. Methods All patients who had optimal primary cytoreductive surgery for stage III ovarian, fallopian tube, or primary peritoneal carcinoma, met eligibility criteria for GOG-172, and received primary chemotherapy at our institution between 2006 and 2013 were identified. Patients who received at least one cycle of adjuvant IV/IP therapy were included in the IP group. Patient characteristics, treatment information, and reason cited for not administering IP therapy were collected. Results Of the patients evaluated, 330 met inclusion criteria. The majority (n = 261, 79%) received at least one IV/IP cycle (median, 6; range, 1-6), and 62% completed 6 cycles. The most common reason for giving IV-only therapy was postoperative status (i.e., delayed wound healing, performance status), accounting for 18 (26%) of the 69 IV-only patients (5% of the entire cohort). Other cited reasons were baseline comorbidities (15%) and IP port complications (12%). Receipt of ≥ 1 cycle of IP chemotherapy (HR 0.51; 95% CI, 0.32-0.80) and no gross residual disease (HR 0.47; 95% CI, 0.31-0.71) were associated with improved overall survival. Conclusion Potentially modifiable factors identified as leading to the use of IV-only chemotherapy were postoperative status and IP port complications, which if altered, could potentially lead to increased IP chemotherapy use. © 2016 Elsevier Inc.
Keywords:	optimal cytoreduction; intraperitoneal chemotherapy; rationale; serous ovarian cancer; gog-172; national cancer institute guideline adherence
Journal Title:	Gynecologic Oncology
Volume:	142
Issue:	1
ISSN:	0090-8258
Publisher:	Elsevier Inc.
Date Published:	2016-07-01
Start Page:	13
End Page:	18
Language:	English
DOI:	10.1016/j.ygyno.2016.05.015
PROVIDER:	scopus
PMCID:	PMC4917455
PUBMED:	27189456
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-84969577648&partnerID=40&md5=1822ee1f16ea85378429037b15eabbb1
Notes:	For Corrigendum see DOI: 10.1016/j.ygyno.2016.07.097 -- Export Date: 1 July 2016 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/94589